Paying for drug approvals--who's using whom?

Since 1992, the United States has relied heavily on the pharmaceutical industry to pay the salaries of FDA scientists who review new drug applications. Dr. Jerry Avorn writes that most federal regulatory agencies do not derive such a large proportion of their operating budgets from the industries they oversee.